Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Bart KoopmanHarry J M GroenMarjolijn J L LigtenbergKatrien GrünbergKim MonkhorstAdrianus J de LangenMirjam C BoelensMarthe S PaatsJan H von der ThüsenWinand N M DinjensNienke SolleveldTom van WezelHans GelderblomLizza E HendriksErnst-Jan M SpeelTom E TheunissenLeonie I KroezeNiven MehraBerber PietAnthonie J van der WekkenArja Ter ElstWim TimensStefan M WillemsRuud W J MeijersWendy W J de LengAnne S R van LindertTeodora RadonicSayed M S HashemiDaniëlle A M HeidemanEd SchuuringLéon C L T van KempenPublished in: The oncologist (2020)
Interpretation of genomic analyses for optimal choice of target therapy for patients with cancer is becoming increasingly complex. A molecular tumor board (MTB) supports oncologists in rationalizing therapy options. However, there is no consensus on the most optimal setup for an MTB, which can affect the quality of recommendations. This study reveals that the eight MTBs associated with tertiary cancer referral centers in The Netherlands are similar in setup and reach a high agreement in recommendations for rare or complex mutational profiles. The Dutch MTB model is based on a collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.